Last week, we covered the controversial approval of the first Alzheimer’s drug in 20 years. Last year, the FDA advisory committee determined that there wasn’t enough support that the treatment is effective. According to a CNN Health article, one member of the committee has resigned in protest of the recent approval of Biogen’s experimental drug that costs $56k/year.
Alzheimer Drug Approval Leads FDA Advisor to Resign
A Mayo Clinic neurologist resigned in protest of the FDA’s questionable approval of aducanumab.
Jun 15, 2021
Recommended
Recommended
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
